Loading…
Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study
To investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling. Between 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to Decem...
Saved in:
| Published in: | PloS one 2024-12, Vol.19 (12), p.e0315376 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | 12 |
| container_start_page | e0315376 |
| container_title | PloS one |
| container_volume | 19 |
| creator | He, Na Song, Lin Lu, Zhaoxia Zeng, Qingsong Jin, Wumei He, Wenrong Yi, Cunjian |
| description | To investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.
Between 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.
1. The three most frequent subtypes of HPV in this data are HPV 16, HPV 52, and HPV 58, all of which are high-risk types; 2. The results of the post-treatment review of HPV infection showed that the overall effective rate of the Paiteling group was better than that of the Interferon group, and the difference in the cumulative effective rate between the two groups was statistically significant (P < 0.001); 3. Comparative analysis of patients with 14 high-risk types of human papillomavirus in a single infection showed that the overall conversion rate in the Paiteling group was 76.3%, higher than that of the Interferon group, which was 36.7%. The difference was statistically significant (P < 0.001).
The overall efficacy of Paiteling for cervical HPV infection is significantly better than that of Interferon, and it is worth promoting its use in the clinic. |
| doi_str_mv | 10.1371/journal.pone.0315376 |
| format | article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3142871773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A819484937</galeid><doaj_id>oai_doaj_org_article_3da80bfa116448d4b5edeb2513fabca7</doaj_id><sourcerecordid>A819484937</sourcerecordid><originalsourceid>FETCH-LOGICAL-d4426-fbb942859e2100d0810a7a9923b2631ed8641fbcc990c2c308c16cd530823a123</originalsourceid><addsrcrecordid>eNqNkkuP0zAQgCMEYpeFf4DAEhKCQ4sdO07CBVUVj0orLeJ1jSb2pHHlxtnYqeiB_467W1CD9oBy8Gj8zWd7MknylNE54zl7s3Hj0IGd967DOeUs47m8l5yzkqczmVJ-_yQ-Sx55v6E044WUD5MzXspMSsnPk19LazqjwBJsmriqPYFo3XvjiWtIaJEsW9OhR7JFbVQMyWcwAWPZmkDfW4OaBEfacQsd6aE31rot7MwwemK6BlUwrntLFmTAMDjfHxI7JD6Mev84edCA9fjkuF4k3z-8_7b8NLu8-rhaLi5nWohUzpq6LkVaZCWmjFJNC0Yhh7JMeZ1KzlAXUrCmVqosqUoVp4ViUuksBikHlvKL5Pmtt7fOV8fO-YqzaM1ZnvNIrG4J7WBT9YPZwrCvHJjqJuGGdQVDMMpixTUUtG6AMSlEoUWdocY6zRhvoFaQR9e742ljHZumsAsD2Il0utOZtlq7XRWNnGY5i4ZXR8Pgrkf0odoar9Ba6NCNNxeXhZCCi4i--Ae9-3lHag3xBfG3uHiwOkirRcFKUYiSHy4-v4OKn8atUXHOGhPzk4LXk4LIBPwZ1jB6X62-fvl_9urHlH15wrYINrTe2fEwSn4KPjtt9d8e_xlw_httKfxl</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3142871773</pqid></control><display><type>article</type><title>Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>He, Na ; Song, Lin ; Lu, Zhaoxia ; Zeng, Qingsong ; Jin, Wumei ; He, Wenrong ; Yi, Cunjian</creator><creatorcontrib>He, Na ; Song, Lin ; Lu, Zhaoxia ; Zeng, Qingsong ; Jin, Wumei ; He, Wenrong ; Yi, Cunjian</creatorcontrib><description>To investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.
Between 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.
1. The three most frequent subtypes of HPV in this data are HPV 16, HPV 52, and HPV 58, all of which are high-risk types; 2. The results of the post-treatment review of HPV infection showed that the overall effective rate of the Paiteling group was better than that of the Interferon group, and the difference in the cumulative effective rate between the two groups was statistically significant (P < 0.001); 3. Comparative analysis of patients with 14 high-risk types of human papillomavirus in a single infection showed that the overall conversion rate in the Paiteling group was 76.3%, higher than that of the Interferon group, which was 36.7%. The difference was statistically significant (P < 0.001).
The overall efficacy of Paiteling for cervical HPV infection is significantly better than that of Interferon, and it is worth promoting its use in the clinic.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0315376</identifier><identifier>PMID: 39656663</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Biological response modifiers ; Biology and Life Sciences ; Cancer therapies ; Carcinogens ; Care and treatment ; Cervical cancer ; Comparative analysis ; DNA, Viral - genetics ; Drugs ; Drugs, Chinese Herbal - administration & dosage ; Drugs, Chinese Herbal - pharmacology ; Drugs, Chinese Herbal - therapeutic use ; Effectiveness ; Female ; Gynecology ; Health services ; Herbal medicine ; Human papillomavirus ; Humans ; Infection ; Infections ; Interferon ; Medical research ; Medical screening ; Medicine and Health Sciences ; Medicine, Chinese Traditional - methods ; Medicine, Experimental ; Medicine, Oriental ; Menstruation ; Middle Aged ; Papillomaviridae - drug effects ; Papillomaviridae - genetics ; Papillomavirus infections ; Papillomavirus Infections - drug therapy ; Papillomavirus Infections - virology ; Papillomaviruses ; Patients ; Population studies ; Retrospective Studies ; Statistical analysis ; Toxicity ; Treatment Outcome ; Vagina ; Young Adult</subject><ispartof>PloS one, 2024-12, Vol.19 (12), p.e0315376</ispartof><rights>Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0009-0007-2288-239X ; 0009-0004-5897-8244</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3142871773/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3142871773?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39656663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Na</creatorcontrib><creatorcontrib>Song, Lin</creatorcontrib><creatorcontrib>Lu, Zhaoxia</creatorcontrib><creatorcontrib>Zeng, Qingsong</creatorcontrib><creatorcontrib>Jin, Wumei</creatorcontrib><creatorcontrib>He, Wenrong</creatorcontrib><creatorcontrib>Yi, Cunjian</creatorcontrib><title>Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.
Between 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.
1. The three most frequent subtypes of HPV in this data are HPV 16, HPV 52, and HPV 58, all of which are high-risk types; 2. The results of the post-treatment review of HPV infection showed that the overall effective rate of the Paiteling group was better than that of the Interferon group, and the difference in the cumulative effective rate between the two groups was statistically significant (P < 0.001); 3. Comparative analysis of patients with 14 high-risk types of human papillomavirus in a single infection showed that the overall conversion rate in the Paiteling group was 76.3%, higher than that of the Interferon group, which was 36.7%. The difference was statistically significant (P < 0.001).
The overall efficacy of Paiteling for cervical HPV infection is significantly better than that of Interferon, and it is worth promoting its use in the clinic.</description><subject>Adult</subject><subject>Biological response modifiers</subject><subject>Biology and Life Sciences</subject><subject>Cancer therapies</subject><subject>Carcinogens</subject><subject>Care and treatment</subject><subject>Cervical cancer</subject><subject>Comparative analysis</subject><subject>DNA, Viral - genetics</subject><subject>Drugs</subject><subject>Drugs, Chinese Herbal - administration & dosage</subject><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Effectiveness</subject><subject>Female</subject><subject>Gynecology</subject><subject>Health services</subject><subject>Herbal medicine</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Infection</subject><subject>Infections</subject><subject>Interferon</subject><subject>Medical research</subject><subject>Medical screening</subject><subject>Medicine and Health Sciences</subject><subject>Medicine, Chinese Traditional - methods</subject><subject>Medicine, Experimental</subject><subject>Medicine, Oriental</subject><subject>Menstruation</subject><subject>Middle Aged</subject><subject>Papillomaviridae - drug effects</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus infections</subject><subject>Papillomavirus Infections - drug therapy</subject><subject>Papillomavirus Infections - virology</subject><subject>Papillomaviruses</subject><subject>Patients</subject><subject>Population studies</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Toxicity</subject><subject>Treatment Outcome</subject><subject>Vagina</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkkuP0zAQgCMEYpeFf4DAEhKCQ4sdO07CBVUVj0orLeJ1jSb2pHHlxtnYqeiB_467W1CD9oBy8Gj8zWd7MknylNE54zl7s3Hj0IGd967DOeUs47m8l5yzkqczmVJ-_yQ-Sx55v6E044WUD5MzXspMSsnPk19LazqjwBJsmriqPYFo3XvjiWtIaJEsW9OhR7JFbVQMyWcwAWPZmkDfW4OaBEfacQsd6aE31rot7MwwemK6BlUwrntLFmTAMDjfHxI7JD6Mev84edCA9fjkuF4k3z-8_7b8NLu8-rhaLi5nWohUzpq6LkVaZCWmjFJNC0Yhh7JMeZ1KzlAXUrCmVqosqUoVp4ViUuksBikHlvKL5Pmtt7fOV8fO-YqzaM1ZnvNIrG4J7WBT9YPZwrCvHJjqJuGGdQVDMMpixTUUtG6AMSlEoUWdocY6zRhvoFaQR9e742ljHZumsAsD2Il0utOZtlq7XRWNnGY5i4ZXR8Pgrkf0odoar9Ba6NCNNxeXhZCCi4i--Ae9-3lHag3xBfG3uHiwOkirRcFKUYiSHy4-v4OKn8atUXHOGhPzk4LXk4LIBPwZ1jB6X62-fvl_9urHlH15wrYINrTe2fEwSn4KPjtt9d8e_xlw_httKfxl</recordid><startdate>20241210</startdate><enddate>20241210</enddate><creator>He, Na</creator><creator>Song, Lin</creator><creator>Lu, Zhaoxia</creator><creator>Zeng, Qingsong</creator><creator>Jin, Wumei</creator><creator>He, Wenrong</creator><creator>Yi, Cunjian</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0007-2288-239X</orcidid><orcidid>https://orcid.org/0009-0004-5897-8244</orcidid></search><sort><creationdate>20241210</creationdate><title>Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study</title><author>He, Na ; Song, Lin ; Lu, Zhaoxia ; Zeng, Qingsong ; Jin, Wumei ; He, Wenrong ; Yi, Cunjian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d4426-fbb942859e2100d0810a7a9923b2631ed8641fbcc990c2c308c16cd530823a123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Biological response modifiers</topic><topic>Biology and Life Sciences</topic><topic>Cancer therapies</topic><topic>Carcinogens</topic><topic>Care and treatment</topic><topic>Cervical cancer</topic><topic>Comparative analysis</topic><topic>DNA, Viral - genetics</topic><topic>Drugs</topic><topic>Drugs, Chinese Herbal - administration & dosage</topic><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Effectiveness</topic><topic>Female</topic><topic>Gynecology</topic><topic>Health services</topic><topic>Herbal medicine</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Infection</topic><topic>Infections</topic><topic>Interferon</topic><topic>Medical research</topic><topic>Medical screening</topic><topic>Medicine and Health Sciences</topic><topic>Medicine, Chinese Traditional - methods</topic><topic>Medicine, Experimental</topic><topic>Medicine, Oriental</topic><topic>Menstruation</topic><topic>Middle Aged</topic><topic>Papillomaviridae - drug effects</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus infections</topic><topic>Papillomavirus Infections - drug therapy</topic><topic>Papillomavirus Infections - virology</topic><topic>Papillomaviruses</topic><topic>Patients</topic><topic>Population studies</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Toxicity</topic><topic>Treatment Outcome</topic><topic>Vagina</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Na</creatorcontrib><creatorcontrib>Song, Lin</creatorcontrib><creatorcontrib>Lu, Zhaoxia</creatorcontrib><creatorcontrib>Zeng, Qingsong</creatorcontrib><creatorcontrib>Jin, Wumei</creatorcontrib><creatorcontrib>He, Wenrong</creatorcontrib><creatorcontrib>Yi, Cunjian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Opposing Viewpoints (Gale)</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals (Open Access)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Na</au><au>Song, Lin</au><au>Lu, Zhaoxia</au><au>Zeng, Qingsong</au><au>Jin, Wumei</au><au>He, Wenrong</au><au>Yi, Cunjian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2024-12-10</date><risdate>2024</risdate><volume>19</volume><issue>12</issue><spage>e0315376</spage><pages>e0315376-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.
Between 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.
1. The three most frequent subtypes of HPV in this data are HPV 16, HPV 52, and HPV 58, all of which are high-risk types; 2. The results of the post-treatment review of HPV infection showed that the overall effective rate of the Paiteling group was better than that of the Interferon group, and the difference in the cumulative effective rate between the two groups was statistically significant (P < 0.001); 3. Comparative analysis of patients with 14 high-risk types of human papillomavirus in a single infection showed that the overall conversion rate in the Paiteling group was 76.3%, higher than that of the Interferon group, which was 36.7%. The difference was statistically significant (P < 0.001).
The overall efficacy of Paiteling for cervical HPV infection is significantly better than that of Interferon, and it is worth promoting its use in the clinic.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39656663</pmid><doi>10.1371/journal.pone.0315376</doi><tpages>e0315376</tpages><orcidid>https://orcid.org/0009-0007-2288-239X</orcidid><orcidid>https://orcid.org/0009-0004-5897-8244</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2024-12, Vol.19 (12), p.e0315376 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_3142871773 |
| source | Open Access: PubMed Central; ProQuest - Publicly Available Content Database |
| subjects | Adult Biological response modifiers Biology and Life Sciences Cancer therapies Carcinogens Care and treatment Cervical cancer Comparative analysis DNA, Viral - genetics Drugs Drugs, Chinese Herbal - administration & dosage Drugs, Chinese Herbal - pharmacology Drugs, Chinese Herbal - therapeutic use Effectiveness Female Gynecology Health services Herbal medicine Human papillomavirus Humans Infection Infections Interferon Medical research Medical screening Medicine and Health Sciences Medicine, Chinese Traditional - methods Medicine, Experimental Medicine, Oriental Menstruation Middle Aged Papillomaviridae - drug effects Papillomaviridae - genetics Papillomavirus infections Papillomavirus Infections - drug therapy Papillomavirus Infections - virology Papillomaviruses Patients Population studies Retrospective Studies Statistical analysis Toxicity Treatment Outcome Vagina Young Adult |
| title | Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A30%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20efficacy%20analysis%20of%20the%20Chinese%20medicine%20Paiteling%20applied%20to%20human%20papillomavirus%20infection:%20A%20retrospective%20study&rft.jtitle=PloS%20one&rft.au=He,%20Na&rft.date=2024-12-10&rft.volume=19&rft.issue=12&rft.spage=e0315376&rft.pages=e0315376-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0315376&rft_dat=%3Cgale_plos_%3EA819484937%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d4426-fbb942859e2100d0810a7a9923b2631ed8641fbcc990c2c308c16cd530823a123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3142871773&rft_id=info:pmid/39656663&rft_galeid=A819484937&rfr_iscdi=true |